Sunday, February 14, 2016

FDA clears BriaCell for BriaVax trial

FDA clears BriaCell for BriaVax trial

November 4, 2015 by · Leave a Comment 

Tweet The FDA has given final clearance for BriaCell Therapeutics’ (OTCQB:BCTXF; TSX-V:BCT) IND to initiate a Phase 1/2a clinical trial of its BriaVax vaccine. The open-label, non-randomized trial will enroll up to 24 breast cancer patients with advanced stages of disease. The clinical trial protocol has a provision to allow testing of the vaccine in […]

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics sets Phase 2 SARM trial

October 30, 2015 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in men with prostate cancer who […]

Can-Fite preparing protocol for advanced psoriasis trial

Can-Fite preparing protocol for advanced psoriasis trial

September 8, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its primary endpoint. The earlier trial was designed to show a statistically significant improvement in the Psoriasis Area Severity Index (PASI) 75 score, […]

Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

August 26, 2015 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly […]

HCW starts Biocept at buy

HCW starts Biocept at buy

August 19, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and $4 price target. The stock closed at $1.96 on Tuesday. Biocept is a commercial-stage company in the emerging field of liquid biopsy, focusing on the capture, enumeration and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood […]

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical seeking CE Mark for TULSA-PRO this year

May 26, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac&feature=youtu.be’]

Tweet Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of prostrate cancer will be sufficient to file for CE Mark approval in Europe before the end of 2015. “We hope to launch TULSA-PRO in […]

Janney starts Advaxis at buy

Janney starts Advaxis at buy

May 15, 2015 by · Leave a Comment 

Tweet Janney Capital Markets has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and fair value estimate of $26. The stock closed at $18.97 on Thursday. Advaxis is built on immunotherapy technology, which utilizes bacteria to stimulate an immune attack on cancer cells. The company is developing candidates for the treatment of HPV-associated cancers, […]

HCW starts Inovio Pharmaceuticals at buy

HCW starts Inovio Pharmaceuticals at buy

March 12, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Inovio Pharmaceuticals (NASDAQ:INO) with a “buy” rating and 12-month price target of $17. The stock closed at $7.17 on Wednesday. Inovio is a highly diversified developer of differentiated DNA-based synthetic vaccines, writes analyst Yi Chen, adding that its DNA vaccines represent a novel and highly effective way to […]

Roth starts Viralytics at buy

Roth starts Viralytics at buy

February 25, 2015 by · Leave a Comment 

Tweet Roth Capital Markets has launched coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and price target of $3.84 (Australian). The company’s lead drug candidate, CAVATAK, has delivered encouraging data in metastatic melanoma and is in expansion studies in multiple tumor types, writes analyst Joseph Pantginis. “We believe this oncolytic virus’ two pronged-mechanism of […]

Analysts launch coverage of Tokai Pharma

Analysts launch coverage of Tokai Pharma

October 13, 2014 by · Leave a Comment 

Tweet Analysts at William Blair, Stifel and Janney Capital Markets initiated coverage of Tokai Pharmaceuticals (NASDAQ:TKAI), saying its lead asset, galeterone, represents a first-in-class and best-in-class, selective and multi-targeted small molecule that should offer advantages over existing prostate cancer therapies. Analyst Katherine Xu started Tokai at “outperform” with a $44 price target. Shares of Tokai […]

Next Page »

Email Newsletters with Constant Contact
Google+